Drugs / MenACWY-PS
MenACWY-PS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00262002 | Sep 2004 → Jul 2005 | meningococcemia | Novartis Vaccines | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01593514 | Dec 2012 → Apr 2013 | bacterial infectious disease with sepsis, meningitis, meningococcal infection | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00329849 Comparator | May 2006 → Mar 2007 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY-PS | “MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent).” NCT00329849 ↗ |
| Known as | ACWYVax | “The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.” NCT01593514 ↗ |
| Known as | MenACWY-CRM | “MenACWY PS (MenACWY-CRM, polysaccharide vaccine)” NCT00262002 ↗ |
| Known as | MPSV4 | “619 healthy children (2-10 years of age) received one dose of an investigational quadrivalent meningococcal CRM(197)-conjugated vaccine (MenACWY-CRM) or a licensed quadrivalent...” PMID 19895922 ↗ Nov 2009 |
| Modality | Vaccine | “MenACWY polysaccharide vaccine” NCT00262002 ↗ |
| Route | Subcutaneous | “One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection” NCT00329849 ↗ |